MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

4.03 -1.23

Buy Sell

Overview

Share price change

24h

Current

Min

3.87

Max

4.09

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+222.74% upside

Market Stats
By TradingEconomics
Market Cap	-28M 227M
Previous open	5.26
Previous close	4.03

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

8 sty 2026, 23:08 UTC

Acquisitions, Mergers, Takeovers

Rio Tinto, Glencore in Talks to Form World's Biggest Miner -- 3rd Update

8 sty 2026, 21:39 UTC

Acquisitions, Mergers, Takeovers

Glencore, Rio Tinto Restart Merger Talks -- 2nd Update

8 sty 2026, 20:54 UTC

Acquisitions, Mergers, Takeovers

Glencore, Rio Tinto Restart Merger Talks -- Update

8 sty 2026, 20:44 UTC

Acquisitions, Mergers, Takeovers

Glencore, Rio Tinto Restart Merger Talks

8 sty 2026, 17:05 UTC

Acquisitions, Mergers, Takeovers

Chinese Anta Sports Products Offers to Buy Pinault Family's Stake in Puma, Reuters Says, Citing Unnamed Sources

8 sty 2026, 16:43 UTC

Major Market Movers

Babcock & Wilcox Shares Rise on Siemens Deal for Data Center Project

8 sty 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

8 sty 2026, 23:37 UTC

Market Talk

Gold Steady, Underpinned by Geopolitical Risks -- Market Talk

8 sty 2026, 22:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 sty 2026, 22:42 UTC

Market Talk

RBA Still Battling a Troubling Inflation Outlook, Says TD -- Market Talk

8 sty 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Glencore, Rio Tinto Confirm Early Merger Talks -- Barrons.com

8 sty 2026, 21:53 UTC

Earnings

These Stocks Moved the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 sty 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8 sty 2026, 21:10 UTC

Acquisitions, Mergers, Takeovers

Rio Tinto Says Current Expectation That Any Deal Would Involve Buying Glencore Via Scheme of Arrangement

8 sty 2026, 21:09 UTC

Market Talk

Oil Rises As Trump Said to Back Russia Sanctions Bill -- Market Talk

8 sty 2026, 21:09 UTC

Acquisitions, Mergers, Takeovers

Rio Tinto Confirms in Talks With Glencore Over Possible Merger

8 sty 2026, 20:21 UTC

Market Talk

U.S. Natural Gas Futures Down Despite Inventory Draw -- Market Talk

8 sty 2026, 19:44 UTC

Market Talk

Gold's Shine Masks Deep Drops in Canada Steel, Aluminum Exports -- Market Talk

8 sty 2026, 18:50 UTC

Market Talk

Mexico's Industrial Production Seen Lower in November -- Market Talk

8 sty 2026, 17:48 UTC

Earnings

These Stocks Are Moving the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More -- Barrons.com

8 sty 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 sty 2026, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8 sty 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

8 sty 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 sty 2026, 16:45 UTC

Market Talk

Goldman Lifts 1H LME Copper Forecast -- Market Talk

8 sty 2026, 16:03 UTC

Market Talk

Global Equities Roundup: Market Talk

8 sty 2026, 16:03 UTC

Market Talk

Currency Markets Could Be Underpricing Medium-Term Risks -- Market Talk

8 sty 2026, 16:02 UTC

Market Talk

U.S. Natural Gas Inventories Fall As Expected -- Market Talk

8 sty 2026, 15:23 UTC

Acquisitions, Mergers, Takeovers

Paramount Defends Its Hostile Bid for Warner -- Update

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

222.74% upside

12 Months Forecast

Average 13.2 USD 222.74%

High 25 USD

Low 8 USD

Based on 7 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.